Response by Henriksen et al Regarding Article, "Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial".

Competing Interests: Disclosures Dr Lang reports research grants from Roche Diagnostics, Astra Zeneca, and Boehringer Ingelheim, as well as consultancy or speaker’s fees from Boehringer Ingelheim, Roche Diagnostics, Myokardia, Pharmacosmos, Akero Therapeutics, CV6 Therapeutics, Jazz Pharma, and Novartis, all outside the submitted work. The other authors report no conflicts.